These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4943208)

  • 21. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.
    Lloyd K; Hornykiewicz O
    Science; 1970 Dec; 170(3963):1212-3. PubMed ID: 5478194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Hornykiewicz O
    Nature; 1973 Jun; 243(5409):521-3. PubMed ID: 4743649
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 24. "Catecholamines" in the brain.
    Weiner WJ; Klawans HL
    N Engl J Med; 1970 Feb; 282(9):513-4. PubMed ID: 5411876
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 26. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 27. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 28. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 29. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 31. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dopa resorption and dopamin estimation in blood of patients with Parkinson's disease (author's transl)].
    Metzel E; Weitbrecht WU
    Arch Psychiatr Nervenkr (1970); 1974; 219(3):231-7. PubMed ID: 4433233
    [No Abstract]   [Full Text] [Related]  

  • 35. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors.
    Ericsson AD
    J Neurol Sci; 1971 Oct; 14(2):193-7. PubMed ID: 5112212
    [No Abstract]   [Full Text] [Related]  

  • 36. [Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].
    Samson M; Bohuon C; Augustin P; Comoy E; Pouliquen A
    Rev Neurol (Paris); 1972 Aug; 127(2):315-7. PubMed ID: 4666641
    [No Abstract]   [Full Text] [Related]  

  • 37. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 38. [L-Dopa in Parkinson's-syndrome. New therapeutic attack?].
    Brockmann AW
    Ther Ggw; 1970 Nov; 109(11):1590-3. PubMed ID: 5486128
    [No Abstract]   [Full Text] [Related]  

  • 39. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P; Gjedde A
    Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.